Aequita Pharmacy
Aequita Pharmacy is a 503A compounding pharmacy based in Kirkland, WA. A government record names semaglutide and tirzepatide at Aequita Pharmacy; the newest is a court record dated September 8, 2026. It fills prescriptions; it doesn’t write them, so you can’t get a GLP-1 from Aequita Pharmacy without a prescription from a licensed clinician.1
How to get a GLP‑1 filled by Aequita PharmacyChecked November 20, 2026 against FDA, CMS and state board records. Every fact links to its source.
Aequita Pharmacy at a glance
How to get a GLP‑1 filled by Aequita Pharmacy
To get a GLP‑1 from Aequita Pharmacy, you first need a prescription: it fills prescriptions; it doesn’t write them or sell without one. An online program takes you through the steps: you fill in a health questionnaire, a licensed clinician reviews it, and if they prescribe, the program’s pharmacy ships the medication to you.
These are the three programs ranked highest on our score. Check that a program ships to your state before you sign up.
- 1Health questionnaire, online
- 2A licensed clinician decides
- 3The pharmacy ships to you
We may earn a commission when you sign up through some links. It never changes our order or scores. How we make money
Prefer your own clinician? You’re free to: ask them to send your prescription to Aequita Pharmacy or another licensed pharmacy.
See every program we rankWhat ties Aequita Pharmacy to GLP‑1s
- Court recordSeptember 8, 2026 · tirzepatideEli Lilly and Company v. Mochi Health Corp., et al., order re motion to dismiss second amended complaint2
“Lilly argues the Aequita Defendants participated in Mochi Health’s “tirzepatide-selling scheme.””
- FDA recallJuly 18, 2025 · semaglutideClass II recall D-0563-2025: Lack of Processing Controls.3
“Semaglutide +Cyanocobalamin 1.5 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.”
- FDA recallJuly 18, 2025 · semaglutideClass II recall D-0564-2025: Lack of Processing Controls.4
“Semaglutide + Cyanocobalamin injection solution, 2.21 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.”
- FDA recallJuly 18, 2025 · semaglutideClass II recall D-0562-2025: Lack of Processing Controls.5
“Semaglutide + Cyanocobalamin 0.88 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.”
- FDA recallJuly 18, 2025 · semaglutideClass II recall D-0553-2025: Lack of Processing Controls.6
“Semaglutide + Cyanocobalamin 0.22 mg + 0.25mg/0.5 ml Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.”
- FDA recallJuly 18, 2025 · semaglutideClass II recall D-0561-2025: Lack of Processing Controls.7
“Semaglutide + Cyanocobalamin 0.44 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.”
- FDA recallJuly 18, 2025 · semaglutideClass II recall D-0565-2025: Lack of Processing Controls.8
“Semaglutide + Cyanocobalamin 2.67 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.”
- FDA recallJuly 18, 2025 · tirzepatideClass II recall D-0555-2025: Lack of Processing Controls.9
“Tirzepatide + Niacinamide 4.4 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.”
- FDA recallJuly 18, 2025 · tirzepatideClass II recall D-0554-2025: Lack of Processing Controls.10
“Tirzepatide + Niacinamide 2.2 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.”
- FDA recallJuly 18, 2025 · tirzepatideClass II recall D-0558-2025: Lack of Processing Controls.11
“Tirzepatide + Niacinamide 11.24 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.”
- FDA recallJuly 18, 2025 · tirzepatideClass II recall D-0560-2025: Lack of Processing Controls.12
“Tirzepatide + Niacinamide 16.6 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 3 x 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.”
- FDA recallJuly 18, 2025 · tirzepatideClass II recall D-0556-2025: Lack of Processing Controls.13
“Tirzepatide + Niacinamide 6.6 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.”
- FDA recallJuly 18, 2025 · tirzepatideClass II recall D-0557-2025: Lack of Processing Controls.14
“Tirzepatide + Niacinamide 8.8 mg + 1.0mg/0.5 ml Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.”
- FDA recallJuly 18, 2025 · tirzepatideClass II recall D-0559-2025: Lack of Processing Controls.15
“Tirzepatide + Niacinamide 13.2 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.”
- State board actionMarch 13, 2025 · semaglutide and tirzepatidePharmacy Quality Assurance Commission issues Limited Stop Service on license of pharmacy (news release 25-034)16
“Aequita, which compounds Glucagon-like peptide-1s (GLP-1s) such as Semaglutide and Tirzepatide, failed to develop and implement a commission-approved plan of correction”
Aequita Pharmacy’s FDA record
No FDA action on file: the FDA’s list of compounding inspections, recalls and warning letters names no action on Aequita Pharmacy. That means we found none, not that the FDA has reviewed it.
What a compounded GLP‑1 is, and what it isn’t
The bigger question with any compounded program is the drug itself. Compounded GLP-1s are prepared by a pharmacy to a prescription. They are not FDA-approved: the FDA doesn’t review their safety, effectiveness or quality before they’re sold, and they are not the same as Wegovy or Zepbound. Formulas can differ from one pharmacy to the next, and some add ingredients such as vitamin B12.1819 Compounding pharmacies are licensed and inspected by state boards of pharmacy; outsourcing facilities (503B) also register with the FDA and are inspected by it. The FDA can issue warning letters when either breaks rules on safety or sterility.17
Aequita Pharmacy: questions
- 1.NPI Registry: AEQUITA PHARMACY LLC (NPI 1598454589)Centers for Medicare & Medicaid Servicesretrieved 2026-11-20↩
- 2.Eli Lilly and Company v. Mochi Health Corp., et al., order re motion to dismiss second amended complaintU.S. District Court for the Northern District of Californiaretrieved 2026-09-08↩“Lilly argues the Aequita Defendants participated in Mochi Health’s “tirzepatide-selling scheme.””
- 3.Class II recall D-0563-2025: Lack of Processing Controls.U.S. Food and Drug Administration, Enforcement Report (openFDA)retrieved 2025-07-18↩“Semaglutide +Cyanocobalamin 1.5 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.”
- 4.Class II recall D-0564-2025: Lack of Processing Controls.U.S. Food and Drug Administration, Enforcement Report (openFDA)retrieved 2025-07-18↩“Semaglutide + Cyanocobalamin injection solution, 2.21 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.”
- 5.Class II recall D-0562-2025: Lack of Processing Controls.U.S. Food and Drug Administration, Enforcement Report (openFDA)retrieved 2025-07-18↩“Semaglutide + Cyanocobalamin 0.88 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.”
- 6.Class II recall D-0553-2025: Lack of Processing Controls.U.S. Food and Drug Administration, Enforcement Report (openFDA)retrieved 2025-07-18↩“Semaglutide + Cyanocobalamin 0.22 mg + 0.25mg/0.5 ml Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.”
- 7.Class II recall D-0561-2025: Lack of Processing Controls.U.S. Food and Drug Administration, Enforcement Report (openFDA)retrieved 2025-07-18↩“Semaglutide + Cyanocobalamin 0.44 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.”
- 8.Class II recall D-0565-2025: Lack of Processing Controls.U.S. Food and Drug Administration, Enforcement Report (openFDA)retrieved 2025-07-18↩“Semaglutide + Cyanocobalamin 2.67 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.”
- 9.Class II recall D-0555-2025: Lack of Processing Controls.U.S. Food and Drug Administration, Enforcement Report (openFDA)retrieved 2025-07-18↩“Tirzepatide + Niacinamide 4.4 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.”
- 10.Class II recall D-0554-2025: Lack of Processing Controls.U.S. Food and Drug Administration, Enforcement Report (openFDA)retrieved 2025-07-18↩“Tirzepatide + Niacinamide 2.2 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.”
- 11.Class II recall D-0558-2025: Lack of Processing Controls.U.S. Food and Drug Administration, Enforcement Report (openFDA)retrieved 2025-07-18↩“Tirzepatide + Niacinamide 11.24 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.”
- 12.Class II recall D-0560-2025: Lack of Processing Controls.U.S. Food and Drug Administration, Enforcement Report (openFDA)retrieved 2025-07-18↩“Tirzepatide + Niacinamide 16.6 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 3 x 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.”
- 13.Class II recall D-0556-2025: Lack of Processing Controls.U.S. Food and Drug Administration, Enforcement Report (openFDA)retrieved 2025-07-18↩“Tirzepatide + Niacinamide 6.6 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.”
- 14.Class II recall D-0557-2025: Lack of Processing Controls.U.S. Food and Drug Administration, Enforcement Report (openFDA)retrieved 2025-07-18↩“Tirzepatide + Niacinamide 8.8 mg + 1.0mg/0.5 ml Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.”
- 15.Class II recall D-0559-2025: Lack of Processing Controls.U.S. Food and Drug Administration, Enforcement Report (openFDA)retrieved 2025-07-18↩“Tirzepatide + Niacinamide 13.2 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.”
- 16.Pharmacy Quality Assurance Commission issues Limited Stop Service on license of pharmacy (news release 25-034)Washington State Department of Health / Pharmacy Quality Assurance Commissionretrieved 2025-03-13↩“Aequita, which compounds Glucagon-like peptide-1s (GLP-1s) such as Semaglutide and Tirzepatide, failed to develop and implement a commission-approved plan of correction”
- 17.Compounding and the FDA: Questions and AnswersU.S. Food and Drug Administration↩
- 18.
- 19.
A pharmacy’s record can change after the day we read it: check its license with its state board before you fill a prescription. An FDA document is an allegation or an observation the FDA has published, not a court finding. This page is educational and is not medical advice.